Collectively, these data suggest that XIAP phosphorylation can be used as a predictive biomarker for the efficacy of AZD5582 in pancreatic cancer treatment, and the use of therapeutic agents that interfere with IAP expression or function, such as AZD5582, may be a promising approach for the treatment of pancreatic cancer and are attractive as adjuvants to conventional chemotherapy. Here, XIAP is linked to pancreatic neoplasm.